Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha

World Journal of Gastroenterology

Volumn 12, Issue 21, 2006, Pages 3338-3343

  Lebensztejn, Dariusz Marek ^a   Sobaniec Lotowska, Maria Elzbieta ^a   Kaczmarski, Maciej ^a   Voelker, Michael ^b   Schuppan, Detlef ^c,d  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Bayer Research   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biopsy; Collagen VI; Fibrogenesis; Fibrosis; Hepatitis B virus; Hyaluronan; Serum marker; Tenascin; TIMP 1

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BIOLOGICAL MARKER; COLLAGEN TYPE 6; HYALURONIC ACID; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ARTICLE; AUTOMATION; BIOASSAY; CHILD; CHILD CARE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PATIENT MONITORING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

EID: 33745310545     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i21.3338     Document Type: Article

References (51)

1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323
2. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P, Schalm SW. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 238-243
3. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-1853
4. Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998; 61: 219-23
5. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995
6. Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, Crivellaro C, Vergani GM, Iorio R, Pace M, Con P, Gatta A. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-718
7. Shindo M, Arai K, Okuno T. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. J Hepatol 1997; 26: 492-497
8. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998; 43: 2573-2576
9. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, Borzio M, Solforosi L, Morabito A, Ideo G, Podda M. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001; 34: 748-755
10. Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M. Long-tern liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 126-133
11. Han HL, Lang ZW. Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment. World J Gastroenterol 2003; 9: 117-121
12. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832
14. Iredale JP. Matrix turnover in fibrogenesis. Hepatogastroenterology 1996; 43: 56-71
15. Regev A, Berho M Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618
16. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457
17. Schuppan D, Stolzel U, Oesterling C, Somasundaram R. Serum assays for liver fibrosis. J Hepatol 1995; 22: 82-88
18. Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004; 50: 1299-1300
19. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160-1174
20. Woynarowski M, Soda J, Sluzewski W, Chmurska-Motyka T, Mizerski J, Czerwionka-Szaflarska M, Mikina M, Karczewska K, Lebensztejn D, Zaleska I, Chlebcewicz-Szuba W, Smukalska E, Korzon M, Wysocki J, Strawinska E, Kowalik-Mikolajewska B, Kuydowicz J, Kownacka M, Kowalczyk J, Mierzejewska-Rudnicka A, Trocha H, Planeta-Malecka I, Wozniakowska-Gesicka T, Wozniak M. HBeAg clearance rate and interferon alfa dose. Pediatric Gastroenterology 2004; 253-256
21. Ropers T, Kroll W, Becka M, Voelker M, Burchardt ER, Schuppan D, Gehrmann M. Enzyme immunoassay for the measurement of human tenascin-C on the Bayer Immuno 1 analyzer. Clin Biochem 2000; 33: 7-13
22. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713
23. Lebensztejn DM, Kaczmarski M, Sobaniec-Lotowska M, Bauer M, Voelker M, Schuppan D. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology 2004; 39: 868-869
24. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-1417
25. Penillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S-61S
26. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481
27. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993; 38: 1480-1484
28. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-1400
29. Intraobserver and intraobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20
30. Trinchet JC. Clinical use of serum markers of fibrosis in chronic hepatitis. J Hepatol 1995; 22: 89-95
31. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378-386
32. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, Mills AS, Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-1172
33. Sobaniec-Lotowska ME, Lebensztejn DM. Histological outcome of chronic hepatitis B in children treated with interferon alpha. World J Gastroenterol 2005; 11: 7179-7182
34. Ozer E, Ozer E, Helvaci M, Yaprak I. Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy. Liver 1999; 19: 369-374
35. Ruiz Moreno M, Jimenez J, Porres JC, Bartolome J, Moreno A, Carreno V. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990; 45: 26-33
36. Ruiz-Moreno M, Rua MJ, Molina J, Moraleda G, Moreno A, Garcia-Aguado J, Carreno V. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991; 13: 1035-1039
37. Gregorio GV, Jara P, Hierro L, Diaz C, de la Vega A, Vegnente A, Iorio R, Bortolotti F, Crivellaro C, Zancan L, Daniels H, Portmann B, Mieli-Vergani G. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23: 700-707
38. Ruiz-Moreno M, Otero M, Millan A, Castillo I, Cabrerizo M, Jimenez FJ, Oliva H, Ramon y Cajal S, Carreno V. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology 1999; 29: 572-575
39. Zheng M, Cai WM, Weng HL, Liu RH. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol 2002; 8: 1073-1076
40. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M Astemborski J, Thomas DL, Moore RE, Afdhal NH. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43: 78-84
41. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, Pockros PJ, Blatt LM, Conrad A, McHutchison JG. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003; 18: 253-257
42. Guechot J, Serfaty L, Bonnand AM, Chazouilleres O, Poupon RE, Poupon R. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000; 32: 447-452
43. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998; 5: 187-192
44. Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001; 36: 399-406
45. Luo R, Yang S, Xie J, Zhao Z, He Y, Yao J. Diagnostic value of five serum markers for liver fibrosis. Zhonghua Ganzangbing Zazhi 2001; 9: 148-150
46. Kobayashi H, Horikoshi K, Yamataka A, Yamataka T, Okazaki T, Lane GJ, Miyano T. Hyaluronic acid: a specific prognostic indicator of hepatic damage in biliary atresia. J Pediatr Surg 1999; 34: 1791-1794
47. Hasegawa T, Sasaki, Kimura T, Hoki M, Okada A, Mushiake S, Yagi M, Imura K. Measurement of serum hyaluronic acid as a sensitive marker of liver fibrosis in biliary atresia. J Pediatr Surg 2000; 35: 1643-1646
48. Wyatt HA, Dhawan A, Cheeseman P, Mieli-Vergani G, Price JF. Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. Arch Dis Child 2002; 86: 190-193
49. Trivedi P, Cheeseman P, Portmann B, Mowat AP. Serum type III procollagen peptide as a non-invasive marker of liver damage during infancy and childhood in extrahepatic biliary atresia, idiopathic hepatitis of infancy and alpha 1 antitrypsin deficiency. Clin Chim Acta 1986; 161: 137-146
50. Danne T, Gruters A, Schuppan D, Quantas N, Enders I, Weber B. Relationship of procollagen type III propeptide-related antigens in serum to somatic growth in healthy children and patients with growth disorders. J Pediatr 1989; 114: 257-260
51. Smedsrod B, Pertoft H Gustafson S, Laurent TC. Scavenger functions of the liver endothelial cell. Biochem J 1990; 266: 313-327